Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis

2000 ◽  
Vol 7 (3) ◽  
pp. 281-289 ◽  
Author(s):  
F. Sellebjerg ◽  
M. Christiansen ◽  
J. Jensen ◽  
J. L. Frederiksen
Keyword(s):  
Multiple Sclerosis ◽  
Optic Neuritis ◽  
High Dose ◽  
Acute Optic Neuritis ◽  
High Dose Methylprednisolone ◽  
Immunological Effects

Identification of patients with acute optic neuritis or attacks of multiple sclerosis who respond to treatment with oral high-dose methylprednisolone

1998 ◽  
Vol 90 (1) ◽  
pp. 98
Author(s):  
F. Sellebjerg ◽  
C.V. Jensen ◽  
H.O. Madsen ◽  
M. Christiansen ◽  
J.L. Frederiksen ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Optic Neuritis ◽  
High Dose ◽  
Acute Optic Neuritis ◽  
High Dose Methylprednisolone

Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis

2003 ◽  
Vol 9 (1) ◽  
pp. 102-107 ◽  
Author(s):  
F Sellebjerg ◽  
C V Jensen ◽  
H BW Larsson ◽  
J L Frederiksen
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Magnetic Resonance ◽  
High Dose ◽  
Resonance Imaging ◽  
Point Change ◽  
Enhanced Mri ◽  
Acute Optic Neuritis ◽  
High Dose Methylprednisolone ◽  
Methylprednisolone Treatment

O ral high-dose methylprednisolone treatment is efficacious in acute optic neuritis (O N) and attacks of multiple sclerosis (MS). The responses to treatment in subgroups of patients participating in two randomized, controlled trials were assessed. Fifty-eight patients with O N and 51 patients with attacks of MS were treated with placebo or oral methylprednisolone (500 mg daily for five days with a 10-day tapering period). A gadolinium (Gd)-enhanced magnetic resonance imaging (MRI) scan was obtained at baseline in 66 patients, and 29 patients underwent repeated MRI studies. Seventy-four patients underwent lumbar puncture before treatment. The odds ratio (O R) of improvement after methylprednisolone treatment (a one point change in the visual function system score of the Kurtzke Expanded Disability Status Scale (EDSS) in O N or in the EDSS score in attacks of MS) was higher in patients with enhancing lesions on baseline MRI (one week: O R 15, P-0.02; eight weeks: O R 4.6, P-0.02). Methylprednisolone treatment suppressed G d-enhancement after one week (P-0.001) and three weeks (P-0.001). C erebrospinal fluid measures of intrathecal inflammation correlated with the area of G d-enhancement but did not correlate as closely with the treatment response as did the results of G d-enhanced MRI. These findings suggest that the resolution of intrathecal inflammation as assessed by G d-enhanced MRI is a major effect of oral high-dose methylprednisolone.

A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis

Neurology ◽  
1999 ◽  
Vol 52 (7) ◽  
pp. 1479-1479 ◽  
Author(s):  
F. Sellebjerg ◽  
H. S. Nielsen ◽  
J. L. Frederiksen ◽  
J. Olesen
Keyword(s):  
Randomized Controlled Trial ◽  
Optic Neuritis ◽  
Controlled Trial ◽  
High Dose ◽  
Randomized Controlled ◽  
Acute Optic Neuritis ◽  
High Dose Methylprednisolone
Sign in / Sign up

Export Citation Format

Share Document